Compare Kimberly Clark Corp (KMB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Recursion Pharmaceuticals Inc — how do they compare? Kimberly Clark Corp trades at $108.57 (market cap $36.48B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Kimberly Clark Corp is far larger — about 20.5× Recursion Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 4.67% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| KMB | RXRX | |
|---|---|---|
Market Cap | $36.48B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $6.79 |
52-Week Low | $93.05 | $2.84 |
Enterprise Value | $42.04B | $1.30B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.68, up 0.94% with a bullish technical signal. The stock shows strong profitability with 11.79% net margin and 129.43% ROE, though Q2 2026 earnings missed estimates. Recent news highlights China market challenges and dividend stability. Current valuation metrics include P/E of 21.68 and P/S of 2.2, with analyst consensus price target of $113.20 suggesting modest upside potential from current levels.
KMB presents a balanced investment case with solid fundamentals offset by near-term headwinds. The company maintains strong brand positioning and dividend consistency, but faces execution risks from China market disruptions and consumer softness. Wall Street maintains cautious optimism with 61% hold ratings, indicating potential for gradual appreciation if operational challenges are managed effectively.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
